Fig. 5: Risk of cardiovascular complications from 22 to 365 days target trials of patients hospitalized for COVID-19. | Nature Communications

Fig. 5: Risk of cardiovascular complications from 22 to 365 days target trials of patients hospitalized for COVID-19.

From: Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study

Fig. 5: Risk of cardiovascular complications from 22 to 365 days target trials of patients hospitalized for COVID-19.The alternative text for this image may have been generated using AI.

A Target trial of nirmatrelvir/ritonavir versus no treatment. B Target trial of molnupiravir versus no treatment. Adjusted HRs (square dots) and 95% CIs (error bars) are presented in (A) and (B). The dashed vertical line in (A) and (B) represents the HR of 1.00. Statistical analysis with two-sided Wald test in (A) and (B). MACE major adverse cardiovascular events. RD risk difference. HR hazard ratio. CI confidence interval.

Back to article page